Moderna Inc. [NASDAQ: MRNA] closed the trading session at $157.40 on 03/01/21. The day’s price range saw the stock hit a low of $145.2501, while the highest price level was $157.7799. The company report on February 25, 2021 that Moderna Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Updates.
2021 Vaccine Manufacturing: Raises lower end of global manufacturing plan for 2021 from 600 million doses to 700 million doses; manufacturing is still working to supply up to 1 billion doses for 2021.
2022 Vaccine Manufacturing: Based on the high demand from around the world for our COVID-19 vaccine and variant-based boosters, making new capital investments to increase capacity up to 1.4 billion doses in 2022.
The stocks have a year to date performance of 50.67 percent and weekly performance of -1.24 percent. The stock has been moved at 131.37 percent over the last six months. The stock has performed -1.35 percent around the most recent 30 days and changed 44.17 percent over the most recent 3-months.
If compared to the average trading volume of 22.82M shares, MRNA reached to a volume of 15322669 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Moderna Inc. [MRNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $160.38 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Moderna Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on February 01, 2021. The new note on the price target was released on December 16, 2020, representing the official price target for Moderna Inc. stock. Previously, the target price had yet another raise from $90 to $150, while Jefferies kept a Hold rating on MRNA stock.
The Average True Range (ATR) for Moderna Inc. is set at 12.14, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 74.31. The Price to Book ratio for the last quarter was 22.52, with the Price to Cash per share for the same quarter was set at 8.64.
MRNA stock trade performance evaluation
Moderna Inc. [MRNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.24. With this latest performance, MRNA shares dropped by -1.35% in over the last four-week period, additionally plugging by 131.37% over the last 6 months – not to mention a rise of 507.02% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 49.58, with the RSI for the last a single of trading hit 46.35, and the three-weeks RSI is set at 52.08 for Moderna Inc. [MRNA]. The present Moving Average for the last 50 days of trading for this stock 144.61, while it was recorded at 151.11 for the last single week of trading, and 94.37 for the last 200 days.
Moderna Inc. [MRNA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc. [MRNA] shares currently have an operating margin of -94.99 and a Gross Margin at +99.01. Moderna Inc.’s Net Margin is presently recorded at -92.99.
Return on Equity for this stock declined to -39.99, with Return on Assets sitting at -16.74.
Moderna Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.40 and a Current Ratio set at 2.40.
Earnings per share (EPS) analysis for Moderna Inc. [MRNA] stock
With the latest financial reports released by the company, Moderna Inc. posted -0.35/share EPS, while the average EPS was predicted by analysts to be reported at -0.35/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Moderna Inc. go to 16.80%.
Moderna Inc. [MRNA]: Insider Ownership positions
There are presently around $31,006 million, or 50.40% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: FLAGSHIP PIONEERING INC. with ownership of 30,871,524, which is approximately 0% of the company’s market cap and around 2.00% of the total institutional ownership; BAILLIE GIFFORD & CO, holding 24,312,271 shares of the stock with an approximate value of $3.83 billion in MRNA stocks shares; and VANGUARD GROUP INC, currently with $3.68 billion in MRNA stock with ownership of nearly -16.155% of the company’s market capitalization.
Positions in Moderna Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 447 institutional holders increased their position in Moderna Inc. [NASDAQ:MRNA] by around 36,518,548 shares. Additionally, 230 investors decreased positions by around 41,975,946 shares, while 67 investors held positions by with 118,493,478 shares. The mentioned changes placed institutional holdings at 196,987,972 shares, according to the latest SEC report filing. MRNA stock had 222 new institutional investments in for a total of 6,603,847 shares, while 46 institutional investors sold positions of 650,291 shares during the same period.